Study to Evaluate Orelabrutinib Tablets in Subjects With Hepatic Impairment and Healthy Subject
Status:
Not yet recruiting
Trial end date:
2023-12-30
Target enrollment:
Participant gender:
Summary
This is an Open-Label, Parallel, Single-dose, Phase I Clinical Study to Evaluate the
Pharmacokinetics and Safety of Orelabrutinib Tablets in Subjects with Varying Degrees of
Hepatic Impairment